Project description:We investigated the transcriptomic changes of human microglia xenotransplanted in a mouse model of AD upon treatment with Lecanamab (Lec) compared to control (IgG1). Single-cell RNA sequencing reveals that Lec treatment induces a transcriptional program in microglia that promotes amyloid plaque removal, involving pathways related to phagocytosis, metabolism, antigen presentation, unfolded protein response, and interferon response.
Project description:Cancer lines were treated with enavatuzumab and a human IgG1 control (MSL109) in vitro. Samples were extracted at various time points and analyzed via genechip. We used microarrays to examine gene expression patterns following treatment with enavatuzamab. Expression changes over time were compared with corresponding data from samples treated with a control.
Project description:We investigated the effect of Lecanemab's Fc effector function on the transcriptomes of human microglia xenotransplanted in a mouse model of AD. We performed Nova-ST spatial transcriptomics analysis on xenografted mice treated with Lecanemab and Lecanemab LALA-PG, a human IgG1 variant designed to abolish Fc-mediated effector functions. We found that treatment with Lecanemab induced phagocytic and lysosomal reprogramming in the microglia surrounding plaques, an effect that was not present upon Lecanemab LALA-PG.
Project description:On the basis of the clear role of Recombinant human IgG1 in the reduction of liver triglyceride (TG) level elevated by high-fat-diet, the potential effector genes of Recombinant human IgG1 are screened by means of transcriptional techniques.
Project description:Cancer lines were treated with enavatuzumab and a human IgG1 control (MSL109) in vitro. Samples were extracted at various time points and analyzed via genechip. We used microarrays to examine gene expression patterns following treatment with enavatuzamab. Expression changes over time were compared with corresponding data from samples treated with a control. 16 samples were analyzed for each cell line, with duplicate samples at 4 different time points (from 6 hours to 3 days) for each of the 2 treatments (enavatuzumab and control).
Project description:Iron accumulation in microglia has been observed in Alzheimer’s disease and other neurodegenerative disorders and is thought to contribute to disease progression through various mechanisms including neuroinflammation. To study the interaction between iron accumulation and inflammation, we treated human induced pluripotent stem cell-derived microglia (iPSC-MG) with an increasing concentration of iron, in combination with inflammatory stimuli such as interferon gamma and amyloid β, and performed RNA sequencing.
Project description:Analysis of human natural killer cells following stimulation with immobilized IgG1 for 4 and 24 hours. Results identified significantly differentially expressed genes in natural killer cells stimulated with immobilized IgG1 providing insight into how antibodies modulate the transcriptome in way that may contribute to cell activation and immune tolerance